CS
BCTXL

Clear Street’s BriaCell Therapeutics Warrant BCTXL Stock Holding History

Clear Street’s Portfolio BCTXL Stock Details BCTXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$107K Buy
+104,196
New +$110K ﹤0.01% 612

Other funds holding BCTXL

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Clear Street's BCTXL Position: Q1 2026 in Review

Clear Street opened a new position in BriaCell Therapeutics Warrant (BCTXL) in Q1 2026: 104,196 shares worth $107K. The stake represents ﹤0.01% of the portfolio and ranks #612 among its holdings.

15 funds tracked by Wall St. Rank hold BCTXL as of Q1 2026.

  • Clear Street held 104,196 shares of BriaCell Therapeutics Warrant worth $107K as of Q1 2026.
  • BriaCell Therapeutics Warrant was a new Clear Street position in Q1 2026.
  • BriaCell Therapeutics Warrant made up ﹤0.01% of Clear Street's portfolio in Q1 2026, its #612 holding.
  • 15 funds tracked by Wall St. Rank held BriaCell Therapeutics Warrant as of Q1 2026.

Based on Clear Street's 13F filing for Q1 2026, filed 15 May 2026.